Comparison of a rational vs. high throughput approach for rapid salt screening and selection

References

• Wermouth CG, Stahl PH. Introduction. In: Stahl PH, Wermuth CG eds. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Zurich: Wiley-VCH, 2002: 1–7.
   Google Scholar
• NELSON E. (1957). Solution rate of theophylline salts and effects from oral administration. J Am Pharm Assoc Am Pharm Assoc (Baltim), 46:607–614.
   PubMedGoogle Scholar
• NELSON E. (1958). Comparative dissolution rates of weak acids and their sodium salts. J Am Pharm Assoc Am Pharm Assoc (Baltim), 47:297–299.
   Google Scholar
• NELSON E, KNOECHEL EL, HAMLIN WE, WAGNER JG. (1962). Influence of the absorption rate of tolbutamide on the rate of decline of blood sugar levels in normal humans. J Pharm Sci, 51:509–514.
   PubMed Web of Science ®Google Scholar
• Sádaba B, Campanero MA, Muñoz-Juarez MJ, Gil-Aldea I, García-Quetglas E, Esteras A et al. (2006). A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers. Eur J Clin Pharmacol, 62:849–854.
   PubMed Web of Science ®Google Scholar
• Furesz S. Blood levels following oral administration of different preparation of novobiocin. Antibiot Chemoth 1958;8:446–449.
   Google Scholar
• Stahl PH, Nakano M. Pharmaceutical aspects of the drug salt form. In: Stahl PH, Wermuth CG eds. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Zurich: Wiley-VCH, 2002: 83–116.
   Google Scholar
• O’Connor KM, Corrigan OI. (2001). Preparation and characterisation of a range of diclofenac salts. Int J Pharm, 226:163–179.
   PubMed Web of Science ®Google Scholar
• Gould PL. Salt selection for basic drugs. Int J Pharm 1986;33:201–217
   Web of Science ®Google Scholar
• Kawakami K, Ida Y, Yamaguchi T. (2005). Effect of salt type on hygroscopicity of a new cephalosporin S-3578. Pharm Res, 22:1365–1373.
   PubMed Web of Science ®Google Scholar
• Berge SM, Bighley LD, Monkhouse DC. (1977). Pharmaceutical salts. J Pharm Sci, 66:1–19.
   PubMed Web of Science ®Google Scholar
• Walking WD, Reynolds BE, Fegely BJ, Janicki CA. Xilobam: effect of salt form on pharmaceutical properties. Drug Dev Ind Pharm 1983;9:809–819.
   Web of Science ®Google Scholar
• Kojima T, Sugano K, Onoue S, Murase N, Sato M, Kawabata Y et al. (2008). Solid form selection of zwitterionic 5-HT4 receptor agonist. Int J Pharm, 350:35–42.
   PubMed Web of Science ®Google Scholar
• Badawy SI. (2001). Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. Int J Pharm, 223:81–87.
   PubMed Web of Science ®Google Scholar
• Huang LF, Tong WQ. (2004). Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev, 56:321–334.
   PubMed Web of Science ®Google Scholar
• Bastin RJ, Bowker MJ, Slater BJ.. (2000). Salt selection and optimization procedures for pharmaceutical new chemical entities. Org Proc Res Dev, 4:427–435.
   Web of Science ®Google Scholar
• Sun C, Grant DJ. (2001). Compaction properties of L-lysine salts. Pharm Res, 18:281–286.
   PubMed Web of Science ®Google Scholar
• Remenar JF, MacPhee JM, Larson BK, Tyagi VA, Ho JH, McIlroy DA, Hickey MB, Shaw PB Almarsson Ö. Salt selection and simultaneous polymorphism assessment via high-throughput crystallization: the case of sertraline. Org Proc Res Dev 2003; 7: 990–996.
   Web of Science ®Google Scholar
• Ware EC, Lu DR. (2004). An automated approach to salt selection for new unique trazodone salts. Pharm Res, 21:177–184.
   PubMed Web of Science ®Google Scholar
• Kojima T, Onoue S, Murase N, Katoh F, Mano T, Matsuda Y. (2006). Crystalline form information from multiwell plate salt screening by use of Raman microscopy. Pharm Res, 23:806–812.
   PubMed Web of Science ®Google Scholar
• Kumar L, Amin A, Bansal AK. (2007). An overview of automated systems relevant in pharmaceutical salt screening. Drug Discov Today, 12:1046–1053.
   PubMed Web of Science ®Google Scholar
• Brittain HG. Strategy for the prediction and selection of drug substance salt forms. Pharm Tech 2007;31:78–88.
   Google Scholar
• Kramer SF, Flynn GL. (1972). Solubility of organic hydrochlorides. J Pharm Sci, 61:1896–1904.
   PubMed Web of Science ®Google Scholar
• Chowhan ZT. (1978). pH-solubility profiles or organic carboxylic acids and their salts. J Pharm Sci, 67:1257–1260.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT, Rosoff M. (1984). pH-Solubility profile of papaverine hydrochloride and its relationship to the dissolution rate of sustained-release pellets. J Pharm Sci, 73:1203–1208.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT, Jarowski CI. (1985). Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts. II: Salicylic acid, theophylline, and benzoic acid. J Pharm Sci, 74:148–154.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT, Jarowski CI. (1985). Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. I: Phenazopyridine. J Pharm Sci, 74:142–147.
   PubMed Web of Science ®Google Scholar
• Serajuddin ATM, Mufson D. pH-solubility profiles of organic bases and their hydrochloride salts. Pharm Res 1985; 2: 65–68.
   PubMedGoogle Scholar
• Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. (1986). Preformulation study of a poorly water-soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design. J Pharm Sci, 75:492–496.
   PubMed Web of Science ®Google Scholar
• Serajuddin ATM, Pudipeddi M. Salt-selection strategies. In: Stahl PH, Wermuth CG eds. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Zurich: Wiley-VCH, 2002: 135–160.
   Google Scholar
• Greene LR, Blackburn AC, Miller JM. (2005). Rapid, small-scale determination of organic solvent solubility using a thermogravimetric analyzer. J Pharm Biomed Anal, 39:344–347.
   PubMed Web of Science ®Google Scholar
• Gu CH, Young V Jr, Grant DJ. (2001). Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci, 90:1878–1890.
   PubMed Web of Science ®Google Scholar
• Miller JM, Collman BM, Greene LR, Grant DJ, Blackburn AC. (2005). Identifying the stable polymorph early in the drug discovery-development process. Pharm Dev Technol, 10:291–297.
   PubMed Web of Science ®Google Scholar
• Gong Y, Collman BM, Mehrens SM, Lu E, Miller JM, Blackburn A et al. (2008). Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine. J Pharm Sci, 97:2130–2144.
   PubMed Web of Science ®Google Scholar
• Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, Spagnuolo Serajuddin, ATM. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 1994;105:209–217.
   Web of Science ®Google Scholar